 |
160 Products |  |
813 Diseases | | 160 Products |
|
1552 Trials |  |
75151 News |  |
| «12...3435363738394041424344...858859» |
- | dazodalibep (HZN-4920) / Amgen
Trial completion date, Trial primary completion date: CONTROL-RA: CD40L Antagonism in Rheumatoid Arthritis (RA) (clinicaltrials.gov) - Sep 5, 2024
P2, N=104, Active, not recruiting, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Trial completion date: Mar 2025 --> Mar 2026 | Trial primary completion date: Aug 2024 --> Aug 2025
- ||| Columvi (glofitamab-gxbm) / Roche, Polivy (polatuzumab vedotin-piiq) / Roche, Rituxan (rituximab) / Roche
Enrollment open: Polatuzumab Vedotin and Combination Chemotherapy With or Without Glofitamab for the Treatment of Untreated Aggressive Large B-cell Lymphoma (clinicaltrials.gov) - Sep 5, 2024
P1, N=68, Recruiting, Sponsor: University of Washington
Trial completion date: Mar 2025 --> Mar 2026 | Trial primary completion date: Aug 2024 --> Aug 2025 Suspended --> Recruiting
- | Enbrel (etanercept) / Pfizer, Amgen
New P1 trial: BRAINWAVES: Safety of a Strategy Combining Etanercept Administration with Repeated Contrast Ultrasound in Patients with Alzheimer's Disease (clinicaltrials.gov) - Sep 4, 2024
P1, N=5, Not yet recruiting, Sponsor: Fondation Ophtalmologique Adolphe de Rothschild
- ||| Aimovig (erenumab-aooe) / Amgen, Novartis
Trial completion date: OASIS (EM): Efficacy and Safety of Erenumab in Pediatric Participants With Episodic Migraine (clinicaltrials.gov) - Sep 4, 2024
P3, N=456, Recruiting, Sponsor: Amgen
Suspended --> Recruiting Trial completion date: May 2027 --> Jun 2026
- || Tepezza (teprotumumab-trbw) / Roche, Amgen, teprotumumab subcutaneous / Xeris Biopharma
Trial completion date: HZNP-TEP-305: A Trial to Investigate Teprotumumab Subcutaneous Administration Compared With Placebo in Male and Female Adult Participants With Moderate-to-severe Active Thyroid Eye Disease (clinicaltrials.gov) - Sep 4, 2024
P3, N=80, Recruiting, Sponsor: Amgen
Trial completion date: May 2027 --> Jun 2026 Trial completion date: Sep 2025 --> May 2026
- | Prolia (denosumab) / Amgen
Enrollment closed: TRIDENT: RANKL Inhibition and Mammographic Breast Density (clinicaltrials.gov) - Sep 4, 2024
P2, N=210, Active, not recruiting, Sponsor: Washington University School of Medicine
Trial completion date: Sep 2025 --> May 2026 Recruiting --> Active, not recruiting
- Asthma biologic therapy and time to next cystic fibrosis pulmonary exacerbation () - Sep 4, 2024 - Abstract #NACFC2024NACFC_1334;
These preliminary results indicate a potential role for asthma biologics in PwCF and may improve control of CF infections in reduction of PEx. Further work on patient selection for these asthma therapies is warranted.
- | Enbrel (etanercept) / Pfizer, Amgen, Humira (adalimumab) / AbbVie
Journal: Frequency and outcomes of treatment dose escalation with biologics in moderate-to-severe psoriasis: a Swedish register study. (Pubmed Central) - Sep 4, 2024
PASI was higher after compared to before dose escalation for etanercept (p?=?0.036), but not for adalimumab (p?=?0.832) or ustekinumab (p?=?0.300). Dose escalation was comparatively more frequent with ustekinumab than with adalimumab or etanercept; however, treatment discontinuation after dose escalation was more common with adalimumab and etanercept than ustekinumab.
- || Ibrance (palbociclib) / Pfizer
Clinical, Journal, HEOR, Real-world evidence, Real-world, Metastases: Palbociclib: Randomized Studies and Real-world Evidence as the Basis for Therapeutic Planning in Metastatic Breast Cancer. (Pubmed Central) - Sep 4, 2024
The aim of this review is to summarize findings from RCTs and RWE considering clinically relevant aspects such as safety, tolerability, quality of life and efficacy with a focus on specific questions and patient characteristics. A critical discussion and review of the overall evidence for endocrine-based therapy with the CDK4/6 inhibitor palbociclib can contribute to support therapy decisions in daily clinical practice.
- || Zyclara (imiquimod) / Mochida, Viatris, Bausch Health, Imlygic (talimogene laherparepvec) / Amgen
Review, Journal: Beyond the Scalpel: Advancing Strategic Approaches and Targeted Therapies in Nonexcisable Melanomas. (Pubmed Central) - Sep 4, 2024
Future research should focus on refining existing treatments and exploring innovative modalities to enhance patient outcomes in the management of nonexcisable melanomas. Comprehensive guidelines and long-term efficacy studies are essential to optimize care and improve the quality of life for patients afflicted with melanoma in challenging anatomical locations.
- || daxdilimab (HZN-7734) / Amgen
Trial completion date, Trial primary completion date: RECAST DLE: Study of Daxdilimab (HZN-7734) in Patients With Moderate-to-Severe Primary Discoid Lupus Erythematosus (clinicaltrials.gov) - Sep 4, 2024
P2, N=99, Recruiting, Sponsor: Amgen
Comprehensive guidelines and long-term efficacy studies are essential to optimize care and improve the quality of life for patients afflicted with melanoma in challenging anatomical locations. Trial completion date: Dec 2024 --> Mar 2025 | Trial primary completion date: Jul 2024 --> Mar 2025
- |||| ordesekimab (AMG 714) / Amgen, Sanofi
Trial completion: PRV-015 in Gluten-free Diet Non-responsive Celiac Disease (clinicaltrials.gov) - Sep 4, 2024
P2, N=226, Completed, Sponsor: Provention Bio, a Sanofi Company
Trial completion date: Dec 2024 --> Mar 2025 | Trial primary completion date: Jul 2024 --> Mar 2025 Active, not recruiting --> Completed
- | Venclexta (venetoclax) / Roche, AbbVie, navtemadlin (KRT-232) / Kartos Therap
Enrollment closed, Combination therapy: Testing a New Chemotherapy Drug, KRT-232 (AMG-232) in Combination With Decitabine and Venetoclax in Patients With Acute Myeloid Leukemia (clinicaltrials.gov) - Sep 4, 2024
P1, N=58, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
Active, not recruiting --> Completed Suspended --> Active, not recruiting
- | Rituxan (rituximab) / Roche
Trial completion, Trial completion date: EPOCH and Rituximab to Treat Non-Hodgkin's Lymphoma in Patients With HIV Infection (clinicaltrials.gov) - Sep 4, 2024
P2, N=68, Completed, Sponsor: National Cancer Institute (NCI)
Suspended --> Active, not recruiting Active, not recruiting --> Completed | Trial completion date: Mar 2027 --> Jan 2024
- | Venclexta (venetoclax) / Roche, AbbVie, Blincyto (blinatumomab) / Astellas, Amgen, Rituxan (rituximab) / Roche
Trial completion date, Trial primary completion date, Combination therapy: NCI-2021-01791: Venetoclax, Dasatinib, Prednisone, Rituximab and Blinatumomab for the Treatment of Newly Diagnosed or Relapsed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia or Mixed Phenotype Acute Leukemia (clinicaltrials.gov) - Sep 4, 2024
P1, N=20, Recruiting, Sponsor: OHSU Knight Cancer Institute
Active, not recruiting --> Completed | Trial completion date: Mar 2027 --> Jan 2024 Trial completion date: Jun 2026 --> Dec 2026 | Trial primary completion date: Jun 2025 --> Dec 2025
- || Verzenio (abemaciclib) / Eli Lilly
Review, Journal, Combination therapy: Practical Guidance on Abemaciclib in Combination with Adjuvant Endocrine Therapy for Treating Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative High-Risk Early Breast Cancer. (Pubmed Central) - Sep 3, 2024
In October 2021, abemaciclib was the first CDK4/6 inhibitor approved in combination with ET by the US Food and Drug Administration for adjuvant treatment of patients with HR-positive, HER2-negative, high-risk early breast cancer. Herein, we provide practical guidance on the use of abemaciclib in combination with ET for HR-positive, HER2-negative, high-risk early breast cancer to assist clinicians in their day-to-day practice, and we review clinically relevant topics of dosing, side effect management, sequencing and optimal timing for initiation, and patient selection.
- Cardiac Sarcoidosis Associated With TNF-alpha Inhibition: Report Of Two Cases. (Exhibit Hall C - ePoster Hub; Monitor 17) - Sep 3, 2024 - Abstract #HFSA2024HFSA_410;
inhibitors like infliximab and adalimumab have also been reported to be effective for the treatment of sarcoidosis associated with etanercept. Further studies are necessary to elucidate the exact mechanisms that underlie the pathophysiology of sarcoidosis associated with etanercept and CZP, and the optimal therapies for these patients.
- | Lumakras (sotorasib) / Amgen
New P2 trial, Metastases: A Study of Sotorasib in People with Non-Small Cell Lung Cancer (clinicaltrials.gov) - Sep 3, 2024
P2, N=39, Recruiting, Sponsor: Memorial Sloan Kettering Cancer Center
- ||| Opdivo (nivolumab) / BMS, Stivarga (regorafenib) / Bayer
Trial completion: Regorafenib Followed by Nivolumab in Patients With Hepatocellular Carcinoma (GOING) (clinicaltrials.gov) - Sep 2, 2024
P1/2, N=69, Completed, Sponsor: Fundacion Clinic per a la Recerca Biom
Further studies are necessary to elucidate the exact mechanisms that underlie the pathophysiology of sarcoidosis associated with etanercept and CZP, and the optimal therapies for these patients. Active, not recruiting --> Completed
- |||||| Enbrel (etanercept) / Pfizer, Amgen
Enrollment open, Adherence: A Study to Learn About the Adherence and Clinical Outcomes in Colombian Patients With an E-Device for Etanercept Administration in Rheumatoid Arthritis (clinicaltrials.gov) - Sep 2, 2024
P=N/A, N=1, Recruiting, Sponsor: Pfizer
Active, not recruiting --> Completed Not yet recruiting --> Recruiting
- |||| PF-06804103 / Pfizer
Trial termination: PF-06804103 Dose Escalation in HER2 Positive and Negative (Negative Only in Part 2) Solid Tumors (clinicaltrials.gov) - Sep 2, 2024
P1, N=95, Terminated, Sponsor: Pfizer
Completed --> Terminated; The trial was terminated based on the stage in drug development and assessment of PF-06804103 relative to the leading external competition. The decision was not due to a safety concern.
- ||| Prolia (denosumab) / Amgen
Enrollment open: Evaluation of Efficacy and Safety of Prolia in Subjects of Male Osteoporosis in Mainland China (clinicaltrials.gov) - Sep 2, 2024
P4, N=100, Recruiting, Sponsor: Amgen
The decision was not due to a safety concern. Not yet recruiting --> Recruiting
- | Journal: Establishment of a trastuzumab-resistant extramammary Paget disease model: loss of PTEN as a potential mechanism. (Pubmed Central) - Sep 2, 2024
Not yet recruiting --> Recruiting This study demonstrates an innovative TR EMPD-PDX model and introduces promising antineoplastic effects with various treatments for TR EMPD tumours.
- | Journal: Reasons for non-feasibility of therapeutic drug monitoring of oral targeted therapies in oncology - an analysis of the closed cohorts of a multicentre prospective study. (Pubmed Central) - Sep 2, 2024
Therefore, routine TDM is not advised for cabozantinib, dabrafenib/trametinib, enzalutamide, erlotinib, everolimus, regorafenib and vismodegib. Nonetheless, TDM remains valuable for individual clinical decisions.
- | Nplate (romiplostim) / Amgen, Kyowa Kirin
Journal, HEOR: Cost-utility analysis of romiplostim for the treatment of chronic primary immune thrombocytopenia in China. (Pubmed Central) - Sep 2, 2024
Probabilistic sensitivity analysis (PSA) indicated that ROMI was likely to be cost effective in 0.16% cases at a willingness-to-pay threshold of $12039.1 (China per capita GDP in 2022) per QALY. If the price of ROMI is either lower than or equal to that of EPAG, ROMI could likely be considered cost-effective as a second-line treatment for Chinese adults with cITP.
- || Prolia (denosumab) / Amgen
Review, Journal: Pharmacological therapy for central giant cell granuloma of the jaws: A systematic review. (Pubmed Central) - Sep 2, 2024
Although the overall success rate in achieving complete resolution is encouraging, further controlled studies are needed to refine drug selection and protocols. Key words:Calcitonin, Central giant cell lesion, Denosumab, Interferon, Pharmacological therapy, Triamcinolone.
- | Neupogen (filgrastim) / Kyowa Kirin, Amgen
Journal: Chondral regeneration in femoroacetabular lesions is favoured using peripheral blood stem cells with hyaluronan-based scaffold and micro-drilling: A prospective cohort study. (Pubmed Central) - Sep 2, 2024
Key words:Calcitonin, Central giant cell lesion, Denosumab, Interferon, Pharmacological therapy, Triamcinolone. One patient (4%) reported a few side effects with filgrastim administration...The intervention suggests a favourable impact on articular cartilage regeneration and clinical outcomes for hip chondral lesions in mixed-FAIS injuries after a median follow-up of 5.1?
- | Neulasta (pegfilgrastim) / Roche
Retrospective data, Journal: A retrospective single institutional analysis of outpatient chemotherapy in patients with cancer during the COVID-19 pandemic. (Pubmed Central) - Sep 2, 2024
Compared to before the first declaration of the state of emergency, the number of chemotherapies decreased except after the declaration, but no decrease was observed during the rest of the period; no difference was observed in the frequency or severity of FN outbreaks or in the use of pegfilgrastim for primary prevention before and after the epidemic. With appropriate treatment guidelines, routine chemotherapy can be performed in an outpatient setting during an outbreak.
- || Blincyto (blinatumomab) / Astellas, Amgen
P2 data, Journal: Reduced-dose chemotherapy and blinatumomab as induction treatment for newly diagnosed Ph-negative B-cell precursor acute lymphoblastic leukemia: a phase 2 trial. (Pubmed Central) - Sep 2, 2024
P2
Trial registration: https://www.clinicaltrials.Gov . Identifier NCT05557110.
- | Neulasta (pegfilgrastim) / Roche
Retrospective data, Journal: Cost of Pegfilgrastim for the Prophylaxis of Chemotherapy-induced Febrile Neutropenia in Patients with Breast Cancer Receiving Perioperative Chemotherapy in Daily Practice in Japan: A Posthoc Analysis in a Single-center Retrospective Study. (Pubmed Central) - Sep 2, 2024
In this single-center retrospective study, we obtained data from 296 Japanese patients with breast cancer receiving fluorouracil, epirubicin, and cyclophosphamide (FEC)-100 chemotherapy; the patients were divided into the pegfilgrastim and non-pegfilgrastim groups...In this study, although the total medical cost in daily practice increased because of primary prophylaxis with pegfilgrastim, the 3-year overall survival was not impacted by the use of pegfilgrastim. Our study data suggested that the primary prophylaxis pegfilgrastim should be used during FEC-100 chemotherapy based on the patient-related FN risk factors, instead of routine use.
- | Ibrance (palbociclib) / Pfizer
Journal: Cyclin-dependent kinase 4 drives cystic kidney disease in the absence of mTORC1 signaling activity. (Pubmed Central) - Sep 2, 2024
Our findings indicate that cystic kidneys rapidly adopt bypass mechanisms typically observed in drug resistant cancers. Thus, future clinical trials need to consider combinatorial or sequential therapies to improve therapeutic efficacy in patients with cystic kidney disease.
- | Ibrance (palbociclib) / Pfizer
Journal: CDK4/6 inhibitor PD-0332991 suppresses hepatocarcinogenesis by inducing senescence of hepatic tumor-initiating cells. (Pubmed Central) - Sep 2, 2024
The SASP factors released by senescent hTICs further activate the immune response, facilitating the clearance of hTICs, and consequently suppressing HCC occurrence. We highlight the importance of pre-HCC interventions and propose that senescence-inducing drugs hold promise for preventing HCC initiation under CLI.
- | Prolia (denosumab) / Amgen
Journal: RANKL/RANK contributes to the pathological process of type 2 diabetes mellitus through TRAF3 activation of NIK. (Pubmed Central) - Sep 2, 2024
Denosumab (DMB) is an effective anti-osteoporotic drug functions by inhibiting NF-?B ligand receptor-activating factor (RANKL)...In summary, RANKL/RANK deficiency may attenuate apoptosis of ?-cells, a phenomenon associated with the TRAF3/NIK pathway. Therefore, RANKL/RANK could be regarded as a potential therapeutic strategy for DM.
- | Prolia (denosumab) / Amgen
Journal: Monoclonal Antibody Delivery Using 3D Printed Biobased Hollow ?Ne3dle Arrays for the Treatment of Osteoporosis. (Pubmed Central) - Sep 2, 2024
It was found that the Dmab administered by the 3D printed ?Ne3dles showed fast in vitro rates and induced an enhanced therapeutic effect in restoring bone-related minerals compared to subcutaneous injections. The findings of this study introduce a novel green approach with a low ecological footprint for 3D printing of biobased ?Ne3dles, which can be tailored to improve clinical outcomes and patient compliance for chronic diseases.
- || Avastin (bevacizumab) / Roche, Lumakras (sotorasib) / Amgen
Preclinical, Retrospective data, Review, Journal, Combination therapy, Checkpoint inhibition, IO biomarker, Metastases: Efficacy of first-line immune checkpoint inhibitor and anti-angiogenic agent combination therapy for Kirsten rat sarcoma viral antigen-mutant advanced non-small-cell lung cancer: a systematic review and network meta-analysis. (Pubmed Central) - Sep 2, 2024
The efficacy of Chemo?+?Bev?+?ICI is potentially high for improving PFS and OS in KRAS-mutant NSCLC. In advanced NSCLC, the presence or absence of KRAS mutations may need to be considered when administering first-line treatment.
- | Tepezza (teprotumumab-trbw) / Roche, Amgen
Journal: TSHR-IGF-IR complex drives orbital fibroblast misbehavior in thyroid eye disease. (Pubmed Central) - Sep 2, 2024
In advanced NSCLC, the presence or absence of KRAS mutations may need to be considered when administering first-line treatment. More detailed understanding of orbital fibroblasts and the distinctions between cell subsets comprising them should lead to more effective therapies with fewer side effects.
- || Imlygic (talimogene laherparepvec) / Amgen
Review, Journal: Advances in Adjuvant and Neoadjuvant Therapy for Melanoma. (Pubmed Central) - Sep 2, 2024
Adjuvant therapy with immune checkpoint blockade (ICB) and targeted therapy with BRAF/MEK inhibitors (BRAF/MEKi) have now become standard of care for resectable stage IIIB-IV melanoma. In this article, the authors discuss recent scientific developments pertinent to the treatment of resectable melanoma including ICB, targeted therapy with BRAF/MEKi, oncolytic viruses, tumor-infiltrating lymphocyte therapy, and cancer vaccines.
- || Tavneos (avacopan) / Amgen
PK/PD data, Journal: Food Effect and Pharmacokinetic Bridging of Avacopan in Caucasian and Japanese Healthy Participants. (Pubmed Central) - Sep 2, 2024
No significant food effect was observed on the active metabolite CCX168-M1 (M1) AUC. Avacopan and M1 exposures were <1.5-fold higher in Japanese participants than in Caucasian participants following multiple-dose administration of avacopan.
- || Tavneos (avacopan) / Amgen
PK/PD data, Journal: Effect of Mild or Moderate Hepatic Impairment on the Pharmacokinetics of Avacopan, a Small-Molecule Complement C5a Receptor Antagonist, for the Treatment of Antineutrophil Cytoplasmic Autoantibody-Associated Vasculitis. (Pubmed Central) - Sep 2, 2024
P1
The geometric mean ratios of metabolite M1 also revealed no pharmacokinetically relevant increase in the peak exposure of M1 in participants with mild or moderate hepatic impairment. Thus, no avacopan dosage adjustment is necessary for patients with mild or moderate hepatic impairment.
- | Prolia (denosumab) / Amgen, Evenity (romosozumab-aqqg) / Astellas, Amgen, UCB
Journal: Change in spinal bone mineral density as estimated by Hounsfield units following osteoporosis treatment with romosozumab, teriparatide, denosumab, and alendronate: an analysis of 318 patients. (Pubmed Central) - Sep 2, 2024
Patients treated with romosozumab for a mean of 10.5 months and teriparatide for a mean of 23 months experienced improved spinal bone mineral density as estimated by CT-based opportunistic HU. Given the shorter duration of effective treatment, romosozumab may be the preferred medication for optimization of osteoporotic patients in preparation for elective spine fusion surgery.
- | Xalkori (crizotinib) / Pfizer, Ibrance (palbociclib) / Pfizer, Zykadia (ceritinib) / Novartis
Journal: A Phosphoramidate Prodrug Platform: One-Pot Amine Functionalization of Kinase Inhibitors with Oligoethylene Glycol for Improved Water-Solubility. (Pubmed Central) - Sep 2, 2024
We observe a slow release at pH 3, while the conjugates remain stable over 96 h under physiological conditions (pH 7.4). Using confocal microscopy, we verify improved cell uptake of the drug-OEG conjugates into the cytoplasm of HeLa cells, further supporting our universal solubility approach.
- || Neulasta (pegfilgrastim) / Roche
Review, Journal: On-body injector pegfilgrastim for chemotherapy-induced neutropenia prophylaxis: Current Status. (Pubmed Central) - Sep 2, 2024
As biosimilar OBIs enter the market, they may offer cost savings, further influencing their adoption and their positioning as a cost-efficient alternative in cancer care. Ongoing research and technological advancements are expected to contribute to the broader acceptance of OBI devices in cancer care delivery.
- | Blincyto (blinatumomab) / Astellas, Amgen, Besponsa (inotuzumab ozogamicin) / Pfizer, UCB, Rituxan (rituximab) / Roche
Journal: Combination low-intensity chemotherapy plus inotuzumab ozogamicin, blinatumomab and rituximab for pediatric patients with relapsed/refractory B-cell acute lymphoblastic leukemia. (Pubmed Central) - Sep 2, 2024
Ongoing research and technological advancements are expected to contribute to the broader acceptance of OBI devices in cancer care delivery. Not available.
- | Ibrance (palbociclib) / Pfizer, Kisqali (ribociclib) / Novartis
Journal, Real-world evidence, Real-world, Metastases: CDK4/6 inhibitors and endocrine therapy in the treatment of metastatic breast cancer: A real-world and propensity score-adjusted comparison. (Pubmed Central) - Sep 2, 2024
While palbociclib may not be superior to traditional endocrine therapy, the results underscore the need for further research. These findings could influence future treatment protocols, emphasizing the importance of personalized therapy in this patient group.
- | Ibrance (palbociclib) / Pfizer
Journal: MYC overexpression in natural killer cell lymphoma: prognostic and therapeutic implications. (Pubmed Central) - Sep 2, 2024
Furthermore, the clinical-grade CDK4/6 inhibitor palbociclib exhibited a potent anti-tumor effect in xenograft mouse models, especially when combined with gemcitabine. In summary, our study firmly establishes MYC as an oncogene with prognostic significance in ENKTL and highlights CDK4 inhibition as a promising therapeutic strategy for treating ENKTL with MYC overexpression.
- || Prolia (denosumab) / Amgen
Review, Journal: Italian position paper (SIPMO-SICMF) on medication-related osteonecrosis of the jaw (MRONJ). (Pubmed Central) - Sep 2, 2024
In summary, our study firmly establishes MYC as an oncogene with prognostic significance in ENKTL and highlights CDK4 inhibition as a promising therapeutic strategy for treating ENKTL with MYC overexpression. The Expert Panel confirmed the MRONJ definition, the diagnostic work-up, the clinical-radiological staging system and the prophylactic drug holiday, as recognized by SIPMO-SICMF; while, it presented novel indications regarding the categories at risk of MRONJ, the prevention strategies, and the treatment strategies associated with the therapeutic drug holiday.
- | Tavneos (avacopan) / Amgen, Rituxan (rituximab) / Roche
Journal: Improved Hearing Impairment of Granulomatosis with Polyangiitis Treated with Rituximab and Avacopan without Glucocorticoids. (Pubmed Central) - Sep 2, 2024
Induction therapy with rituximab and avacopan without glucocorticoids promptly resolved her fever and thigh pain and improved her auditory acuity and nodule in the right lung. The patient experienced no adverse effects with rituximab or avacopan.
- || Evenity (romosozumab-aqqg) / Astellas, Amgen, UCB
Retrospective data, Review, Journal: Effects of romosozumab combined with routine therapy on pain relief, disease progression and adverse reactions in patients with postmenopausal osteoporosis: a systematic review and meta-analysis. (Pubmed Central) - Sep 1, 2024
Combining romosozumab with conventional therapy effectively treats PMOP, significantly reducing vertebral, non-vertebral, and clinical fractures while increasing BMD in the hip, femoral neck, and lumbar spine. However, further high-quality studies are needed for validation.
- | Stivarga (regorafenib) / Bayer
Journal: Small HBV surface antigen (Pubmed Central) - Sep 1, 2024
A substantial body of literature, including our own, points to a connection between hepatitis B virus (HBV) infection and the development of drug resistance in hepatocellular carcinoma (HCC), particularly against sorafenib. In conclusion, SHBs promoted HCC progression and regorafenib resistance via KIAA1429-mediated
- | Tevimbra (tislelizumab-jsgr) / BeiGene, Stivarga (regorafenib) / Bayer
Journal, Metastases: Analysis of efficacy and safety for the combination of tislelizumab and regorafenib in advanced hepatocellular carcinoma: A prospective clinical study. (Pubmed Central) - Sep 1, 2024
In conclusion, SHBs promoted HCC progression and regorafenib resistance via KIAA1429-mediated This study suggests that tislelizumab + regorafenib can be used as a second-line treatment for advanced HCC.